Market Assessment, Rheumatoid Arthritis [Tofacitinib Xeljanz Wave 5 ] LaunchTrends US 2014 Report

This report is a series of four post-launch reports that evaluates the trial and usage of XELJANZ (tofacitinib) among rheumatologists for the treatment of rheumatoid arthritis (RA).
LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products at one month, three months, six months and one year post launch. These report series provide information on how new products fit into the treatment algorithm, impact current therapies, and change market dynamics. They provide information on awareness, familiarity, and perceived clinical advantages and disadvantages of new products.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Rheumatoid Arthritis [Tofacitinib (Xeljanz) (Wave 5)] | LaunchTrends | US | 2014

Related Market Assessment Reports

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Pulmonary Hypertension – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)

Crohn’s Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Pediatric Crohn’s Disease (US)

Chronic Kidney Disease – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)